How Does Gushengtang Holdings Company Work?

How does Gushengtang Holdings deliver modern TCM at scale?

Gushengtang Holdings Limited achieved 3.85 billion RMB revenue in 2025 by scaling a nationwide Online-Merge-Offline (OMO) TCM model across major cities. It combines standardized clinics, digital patient channels, and centralized supply to serve millions annually.

Gushengtang operates through a franchise-like clinical network, telemedicine platforms, and integrated ERP for herbs and prescriptions, enabling consistent care quality and margin control. Key strengths include service standardization and digital-to-physical patient conversion.

Read strategic analysis: Gushengtang Holdings Porter's Five Forces Analysis

Gushengtang integrates top-tier TCM expertise with an OMO platform that enables online booking, HD remote diagnosis, and herbal prescriptions delivered within 24–48 hours, serving elderly chronic patients and younger urban professionals seeking preventive care.

Patient-facing OMO Platform

The platform centralizes appointment booking, video consultations, e-prescriptions and delivery tracking, reducing wait times and improving continuity of care.

Rapid Prescription Fulfillment

Centralized pharmacies prepare bespoke decoctions and ship via optimized logistics to reach patients within 24–48 hours in major cities.

Traceable Supply Chain

Herbs are sourced from standardized cultivation bases with traceability and quality controls to reduce adulteration risk and meet regulatory standards.

Multi-site Physician Model

Partnerships with public hospitals enable top-tier TCM physicians to consult across Gushengtang clinics, increasing access to high-end talent without full-time hospital transfers.

The operational backbone combines a proprietary physician management system, a data-driven CRM tracking outcomes, and centralized logistics that together underpin the Gushengtang business model and how Gushengtang works in practice.

Operational Differentiators and Metrics

Key elements drive value capture and scalability across urban markets.

• High-quality sourcing: partnerships with standardized bases covering a significant portion of medicinal herb inputs, improving safety and efficacy.
• Physician access: multi-site practice model increases specialist consultations availability by leveraging existing hospital talent pools.
• Delivery performance: centralized fulfillment achieves 24–48 hour delivery in primary metro areas, supporting repeat use.
• Data-driven care: CRM records patient outcomes and adherence, enabling iterative treatment optimization and higher retention.

For a strategic view linking operations to growth initiatives, see Growth Strategy of Gushengtang Holdings.

Gushengtang’s revenue is split between Medical and Health Solutions and Sales of Medical and Health Products, with the former contributing about 89% of total revenue by end-2025 through clinical services, and the latter contributing 11% via TCM products and wellness goods.

Clinical services as primary driver

Consultation fees, diagnostics and physical treatments such as acupuncture, tui-na and moxibustion form the bulk of revenue under Medical and Health Solutions.

Tiered pricing model

Pricing varies by physician seniority and specialization, capturing premium value from high-demand specialists while retaining lower-cost primary care options.

Product sales mix

TCM decoction pieces, granules and pre-packaged herbal teas and supplements constitute the Sales of Medical and Health Products segment.

Subscription membership growth

Membership subscriptions rose 28% year-over-year in 2025, boosting recurring revenue and increasing customer lifetime value.

Cross-selling strategy

Patients receiving acute care are frequently converted into long-term wellness product buyers, increasing average revenue per patient.

Geographic revenue dynamics

Tier-1 cities remain the largest revenue source, while Tier-2 city expansion delivered 35% revenue growth in the most recent fiscal period.

Monetization combines fee-for-service clinical income with product sales and recurring memberships; this blended model underpins Gushengtang Holdings operations and illustrates how Gushengtang works across treatment and retail channels.

Revenue levers and metrics

Key levers include pricing segmentation, membership penetration, product attach rate and geographic expansion. Recent metrics reflect the strategy's effectiveness.

• Medical and Health Solutions: 89% of revenue (2025)
• Sales of Medical and Health Products: 11% of revenue (2025)
• Membership YoY growth: 28% (2025)
• Tier-2 city revenue growth: 35% (most recent fiscal period)

For further detail on pricing, membership and go-to-market tactics see Marketing Strategy of Gushengtang Holdings

Key milestones include the 2025 completion of a strategic acquisition phase integrating 12 regional TCM centers, and the 2024 launch of an AI-driven TCM diagnostic assistant that improved prescription accuracy and online operational efficiency by 20%. The company’s competitive edge rests on a network of over 36,000 registered TCM physicians, strong brand retention, and procurement economies of scale.

Key Milestones

2024: launched an AI-driven TCM diagnostic assistant; 2025: completed consolidation of 12 regional centers to solidify national footprint and integrated services across clinics and online platforms.

Strategic Moves

Diversified into out-of-pocket wellness and anti-aging services to offset reimbursement risk, and implemented a physician-partner equity model to retain top talent and align incentives.

Competitive Edge

Unrivaled clinical network of over 36,000 registered physicians, patient retention above 67%, and lower COGS from scale in herbal procurement drive margin advantage versus smaller peers.

Operational Impact

AI diagnostics improved prescription accuracy and online efficiency by 20%, supporting higher throughput and consistency across Gushengtang Holdings operations and patient service flow.

Recent financial and operational data show the move to diversify services helped sustain revenue mix despite reimbursement uncertainty; patient retention and scale reduced churn and lowered average COGS per prescription.

Strategic Advantages and Risks

The company’s model combines nationwide clinic integration, proprietary AI, and physician equity partnerships to defend market share while navigating regulatory and reimbursement headwinds.

• Defensible talent moat via long-term cooperation agreements and equity incentives
• Economies of scale in herbal procurement lowering COGS versus smaller rivals
• Service diversification into wellness and anti-aging to mitigate insurance policy risk
• Regulatory standardization of TCM reimbursement remains a material external risk

For a compact company history and context on how Gushengtang works within integrated healthcare, see Brief History of Gushengtang Holdings

Gushengtang holds the leading position among private TCM healthcare providers in China, with the largest market share, extensive geographic reach, and rising international presence, notably in Southeast Asia; however, it faces regulatory and supply-chain risks that could affect margins and operations.

Industry position

Gushengtang currently leads private TCM providers by revenue and clinic footprint, supported by high customer loyalty and expanding overseas operations; the company captures a significant portion of the estimated 1.2 trillion RMB TCM market.

Market share and scale

As of 2025 the company outperforms nearest competitors across provinces and city tiers, leveraging a large clinic network and digital platforms that reinforce patient retention and referral flows.

Key risks

Regulatory shifts on physician multi-site practice and raw herb price volatility are material risks; certain herbal categories spiked by 12 percent in late 2025 due to climate-driven supply disruptions.

Financial and supply pressures

Cost inflation in input materials and potential reimbursement or licensing changes could compress margins and require operational adjustments across the Gushengtang business model.

Strategically, Gushengtang is integrating digital capabilities into traditional practice to scale chronic-disease management and personalize care via data-driven protocols, positioning itself to capture projected market growth.

Future outlook and strategic priorities

Management emphasizes Smart TCM, M&A, and digital therapeutics to deepen lifetime-care relationships and expand service lines; the market is forecast to grow at a 18 percent CAGR through 2028, creating expansion opportunities.

• Invest in big data and digital platforms to personalize treatments and optimize clinic operations.
• Pursue M&A to expand geographic reach and integrate complementary service providers.
• Develop chronic disease programs to increase long-term patient value and recurring revenue.
• Hedge supply-chain exposure and diversify raw material sourcing to mitigate herb-price volatility.

For additional context on competitors and market positioning see Competitors Landscape of Gushengtang Holdings which details comparative scale, clinic models, and regional strategies relevant to understanding Gushengtang Holdings operations and how Gushengtang works.